These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35528984)

  • 1. Irreversible Electroporation for Hepatocellular Carcinoma Abutting the Diaphragm: A Prospective Single-center Study.
    Ma Y; Chen Z; Liang B; Li R; Li J; Li Z; Lin M; Niu L
    J Clin Transl Hepatol; 2022 Apr; 10(2):190-196. PubMed ID: 35528984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Percutaneous Argon-Helium Cryoablation for Hepatocellular Carcinoma Abutting the Diaphragm.
    Yang Y; Zhang Y; Wu Y; Chen J; Liang B; Chen Q; Wang Q; Lyu J; Li Y; Mu F; Du D
    J Vasc Interv Radiol; 2020 Mar; 31(3):393-400.e1. PubMed ID: 31987705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience.
    Kalra N; Gupta P; Gorsi U; Bhujade H; Chaluvashetty SB; Duseja A; Singh V; Dhiman RK; Chawla YK; Khandelwal N
    Cardiovasc Intervent Radiol; 2019 Apr; 42(4):584-590. PubMed ID: 30697637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.
    Sutter O; Calvo J; N'Kontchou G; Nault JC; Ourabia R; Nahon P; Ganne-Carrié N; Bourcier V; Zentar N; Bouhafs F; Sellier N; Diallo A; Seror O
    Radiology; 2017 Sep; 284(3):877-886. PubMed ID: 28453431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of irreversible electroporation for recurrent hepatocellular carcinoma ineligible for thermal ablation after surgery.
    Wang W; Hou S; Ni J; Sun H; Jiang X; Chen Y; Xu L
    J Interv Med; 2020 Sep; 3(3):151-155. PubMed ID: 34805927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irreversible electroporation of hepatocellular carcinoma and colorectal cancer liver metastases: A nationwide multicenter study with short- and long-term follow-up.
    Frühling P; Stillström D; Holmquist F; Nilsson A; Freedman J
    Eur J Surg Oncol; 2023 Nov; 49(11):107046. PubMed ID: 37716017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial.
    Meijerink MR; Ruarus AH; Vroomen LGPH; Puijk RS; Geboers B; Nieuwenhuizen S; van den Bemd BAT; Nielsen K; de Vries JJJ; van Lienden KP; Lissenberg-Witte BI; van den Tol MP; Scheffer HJ
    Radiology; 2021 May; 299(2):470-480. PubMed ID: 33724066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Incomplete Irreversible Electroporation (IRE) and Microwave Ablation (MWA) of Hepatocellular Carcinoma (HCC) Using Iodine Quantification in Dual Energy Computed Tomography (DECT).
    Bäumler W; Beyer LP; Lürken L; Wiggermann P; Stroszczynski C; Dollinger M; Schicho A
    Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison.
    Freeman E; Cheung W; Ferdousi S; Kavnoudias H; Majeed A; Kemp W; Roberts SK
    Scand J Gastroenterol; 2021 Aug; 56(8):942-947. PubMed ID: 34057003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes.
    Cheung W; Kavnoudias H; Roberts S; Szkandera B; Kemp W; Thomson KR
    Technol Cancer Res Treat; 2013 Jun; 12(3):233-41. PubMed ID: 23369152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
    Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
    Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous radiofrequency ablation for the hepatocellular carcinoma abutting the diaphragm: assessment of safety and therapeutic efficacy.
    Kang TW; Rhim H; Kim EY; Kim YS; Choi D; Lee WJ; Lim HK
    Korean J Radiol; 2009; 10(1):34-42. PubMed ID: 19182501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study.
    Scheffer HJ; Vroomen LG; de Jong MC; Melenhorst MC; Zonderhuis BM; Daams F; Vogel JA; Besselink MG; van Kuijk C; Witvliet J; de van der Schueren MA; de Gruijl TD; Stam AG; van den Tol PM; van Delft F; Kazemier G; Meijerink MR
    Radiology; 2017 Feb; 282(2):585-597. PubMed ID: 27604035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and safety of irreversible electroporation (IRE) in patients with small renal masses: Results of a prospective study.
    Buijs M; Zondervan PJ; de Bruin DM; van Lienden KP; Bex A; van Delden OM
    Urol Oncol; 2019 Mar; 37(3):183.e1-183.e8. PubMed ID: 30509869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic resection
    Song KD; Lim HK; Rhim H; Lee MW; Kang TW; Paik YH; Kim JM; Joh JW
    World J Gastrointest Oncol; 2019 Mar; 11(3):227-237. PubMed ID: 30918595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results.
    Frühling P; Nilsson A; Duraj F; Haglund U; Norén A
    Eur J Surg Oncol; 2017 Apr; 43(4):751-757. PubMed ID: 28109674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre.
    Freeman E; Cheung W; Kavnoudias H; Majeed A; Kemp W; Roberts SK
    Cardiovasc Intervent Radiol; 2021 Feb; 44(2):247-253. PubMed ID: 33051707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety and Efficacy of Irreversible Electroporation for Large Hepatocellular Carcinoma.
    Zeng J; Liu G; Li ZH; Yang Y; Fang G; Li RR; Xu KC; Niu L
    Technol Cancer Res Treat; 2017 Feb; 16(1):120-124. PubMed ID: 27837054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous Irreversible Electroporation (IRE) of Hepatic Malignancy: A Bi-institutional Analysis of Safety and Outcomes.
    Mafeld S; Wong JJ; Kibriya N; Stenberg B; Manas D; Bassett P; Aslam T; Evans J; Littler P
    Cardiovasc Intervent Radiol; 2019 Apr; 42(4):577-583. PubMed ID: 30465255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial).
    Scheffer HJ; Vroomen LG; Nielsen K; van Tilborg AA; Comans EF; van Kuijk C; van der Meijs BB; van den Bergh J; van den Tol PM; Meijerink MR
    BMC Cancer; 2015 Oct; 15():772. PubMed ID: 26497813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.